Clinical Trial Update: A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating teclistamab in previously treated light-chain (AL) amyloidosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: European Myeloma Network B.V. | Conditions: AL Amyloidosis | Phase 2 | Status: RECRUITING